• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酶替代治疗与传统治疗的苯丙酮尿症患者微生物组和饮食差异的初步研究。

Preliminary Investigation of Microbiome and Dietary Differences in Patients with Phenylketonuria on Enzyme Substitution Therapy Compared to Traditional Therapies.

机构信息

Department of Pediatrics, Division of Genetics and Metabolism, University of Kentucky, Lexington, Kentucky.

Department of Nutrition and Exercise Physiology, School of Medicine, University of Missouri, Columbia, Missouri.

出版信息

J Acad Nutr Diet. 2022 Jul;122(7):1283-1295.e3. doi: 10.1016/j.jand.2021.12.011. Epub 2021 Dec 28.

DOI:10.1016/j.jand.2021.12.011
PMID:34968752
Abstract

BACKGROUND

Phenylketonuria (PKU) is an inborn error of metabolism that impairs the function of the enzyme phenylalanine hydroxylase. Historical treatment includes limiting dietary phenylalanine (Phe) consumption while supplementing with medical food; however, this treatment has been associated with complications, such as nutritional deficiencies and disruptions in the gut microbiota.

OBJECTIVE

The study aim was to compare dietary and gut microbiome differences between adult patients on a traditional PKU diet with those receiving the enzyme substitution therapy Palynziq on a liberalized diet while controlling blood Phe levels to <600 μmol/L (to convert to mg/dL divide by 60.5).

DESIGN

A cross-sectional study was conducted comparing patients on a traditional Phe-restricted diet with patients receiving Palynziq eating a liberalized diet.

PARTICIPANTS/SETTING: Six patients eating a traditional Phe-restricted diet with medical food and 6 patients on Palynziq eating a liberalized diet without medical food intake for more than 3 years were selected from the University of Kentucky Metabolic Clinic from August to December 2019.

MAIN OUTCOME MEASURES

Nutrient intake from 3-day diet records and fecal microbiome taxonomic abundances were analyzed.

STATISTICAL ANALYSIS

Mann-Whitney U tests were used for dietary data analysis. Differential abundance analysis for microbiome taxa and pathway data was done using DESeq2 analysis.

RESULTS

Dietary data showed patients receiving Palynziq consumed a lower percent of kilocalories from total protein and lower amounts of most micronutrients, but consumed greater amounts of intact protein and cholesterol (P < .05). Microbiome data revealed a greater abundance of the phylum Verrucomicrobia and genus Lachnobacterium in the Traditional group and a greater abundance of the genus Prevotella in the Palynziq group (P < .05). Pathway analysis depicted greater enrichment in carotenoid and amino acid metabolism pathways in the Traditional group (P < .05). Protein (% kcal), dietary fiber (g), fat (% kcal), linolenic acid (% Dietary Reference Intakes), and age were correlated with the underlying microbial community structure for both groups combined.

CONCLUSIONS

Patients with PKU treated with Palynziq on a liberalized diet manifest significant differences in diet composition compared with those treated with traditional Phe-restricted diets. Several of these dietary differences may affect the microbiome architecture.

摘要

背景

苯丙酮尿症(PKU)是一种代谢性先天缺陷病,会损害苯丙氨酸羟化酶的功能。传统治疗方法包括限制饮食中的苯丙氨酸(Phe)摄入量,同时补充特殊医学用途配方食品;然而,这种治疗方法会引起营养缺乏和肠道微生物群紊乱等并发症。

目的

本研究旨在比较接受传统 PKU 饮食治疗的患者与接受酶替代治疗 Palynziq 治疗且血苯丙氨酸(Phe)水平控制在<600 μmol/L(换算成 mg/dL 除以 60.5)的患者在饮食和肠道微生物群方面的差异。

设计

本研究为 2019 年 8 月至 12 月期间在肯塔基大学代谢诊所进行的一项传统 Phe 限制饮食组与接受 Palynziq 治疗且自由饮食(不摄入特殊医学用途配方食品)超过 3 年的 Palynziq 治疗组患者的横断面研究。

参与者/设置:从肯塔基大学代谢诊所选择 6 名接受传统 Phe 限制饮食联合特殊医学用途配方食品治疗的患者和 6 名接受 Palynziq 治疗且自由饮食(不摄入特殊医学用途配方食品)超过 3 年的患者。

主要观察指标

3 天饮食记录中的营养素摄入量和粪便微生物群分类丰度。

统计学分析

采用 Mann-Whitney U 检验进行饮食数据分析。采用 DESeq2 分析对微生物群分类和途径数据进行差异丰度分析。

结果

饮食数据显示,接受 Palynziq 治疗的患者摄入的总蛋白热量百分比和大多数微量营养素的量较低,但摄入的完整蛋白和胆固醇较多(P <.05)。微生物组数据显示,传统组中厚壁菌门和lachnobacterium 属的丰度较高,而 Palynziq 组中普雷沃氏菌属的丰度较高(P <.05)。途径分析显示,传统组中类胡萝卜素和氨基酸代谢途径的富集程度较高(P <.05)。两组患者的蛋白质(%kcal)、膳食纤维(g)、脂肪(%kcal)、亚麻酸(%膳食参考摄入量)和年龄与基础微生物群落结构呈正相关。

结论

接受 Palynziq 治疗的 PKU 患者与接受传统 Phe 限制饮食治疗的患者相比,饮食结构存在显著差异。这些饮食差异中的一些可能会影响微生物组的结构。

相似文献

1
Preliminary Investigation of Microbiome and Dietary Differences in Patients with Phenylketonuria on Enzyme Substitution Therapy Compared to Traditional Therapies.酶替代治疗与传统治疗的苯丙酮尿症患者微生物组和饮食差异的初步研究。
J Acad Nutr Diet. 2022 Jul;122(7):1283-1295.e3. doi: 10.1016/j.jand.2021.12.011. Epub 2021 Dec 28.
2
Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Analysis of phase 3 clinical trial data.评估聚乙二醇化苯丙氨酸解氨酶治疗对苯丙酮尿症成人患者饮食的影响:3期临床试验数据分析
Mol Genet Metab. 2024 Mar;141(3):108122. doi: 10.1016/j.ymgme.2023.108122. Epub 2023 Dec 24.
3
Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.培维索酶与成人苯丙酮尿症标准治疗比较对照的长期疗效比较。
Mol Genet Metab. 2019 Sep-Oct;128(1-2):92-101. doi: 10.1016/j.ymgme.2019.07.018. Epub 2019 Aug 7.
4
Nutrition status of adults with phenylketonuria treated with pegvaliase.使用聚乙二醇化尿酸酶治疗的苯丙酮尿症成人的营养状况。
Mol Genet Metab. 2021 Aug;133(4):345-351. doi: 10.1016/j.ymgme.2021.06.002. Epub 2021 Jun 7.
5
Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.培加酶用于治疗苯丙酮尿症:2 期剂量确定研究的结果及长期随访。
Mol Genet Metab. 2020 Aug;130(4):239-246. doi: 10.1016/j.ymgme.2020.06.006. Epub 2020 Jun 16.
6
First successful outcomes of pegvaliase (PALYNZIQ) in children.培维索酶(PALYNZIQ)在儿童中取得的首次成功结果。
BMC Med Genomics. 2024 Mar 21;17(1):76. doi: 10.1186/s12920-024-01847-1.
7
Gut-Microbiome Composition in Response to Phenylketonuria Depends on Dietary Phenylalanine in BTBR Pah Mice.BTBR Pah小鼠中肠道微生物群组成对苯丙酮尿症的反应取决于膳食苯丙氨酸。
Front Nutr. 2022 Jan 4;8:735366. doi: 10.3389/fnut.2021.735366. eCollection 2021.
8
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).培加酶用于治疗苯丙酮尿症:长期 3 期临床试验项目(PRISM)的结果。
Mol Genet Metab. 2018 May;124(1):27-38. doi: 10.1016/j.ymgme.2018.03.006. Epub 2018 Mar 31.
9
Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria.聚乙二醇化苯丙氨酸解氨酶在日本苯丙酮尿症成年患者中的两年中期安全性和有效性
Mol Genet Metab. 2023 Nov;140(3):107697. doi: 10.1016/j.ymgme.2023.107697. Epub 2023 Sep 9.
10
Palynziq clinic: One year and 43 patients later.帕利佐尼治疗中心:一年,43 名患者之后。
Mol Genet Metab. 2021 Jul;133(3):250-256. doi: 10.1016/j.ymgme.2021.05.006. Epub 2021 May 19.

引用本文的文献

1
The relationship between adult phenylketonuria and the cardiovascular system - insights into mechanisms and risks.成人苯丙酮尿症与心血管系统的关系——对机制和风险的见解
Orphanet J Rare Dis. 2025 Apr 2;20(1):156. doi: 10.1186/s13023-025-03686-4.
2
Current Insights into Nutritional Management of Phenylketonuria: An Update for Children and Adolescents.苯丙酮尿症营养管理的最新见解:儿童和青少年最新情况
Children (Basel). 2025 Feb 7;12(2):199. doi: 10.3390/children12020199.
3
Body Composition Evaluation and Clinical Markers of Cardiometabolic Risk in Patients with Phenylketonuria.
苯丙酮尿症患者的身体成分评估和心血管代谢风险的临床标志物。
Nutrients. 2023 Dec 18;15(24):5133. doi: 10.3390/nu15245133.
4
Systematic Review and Meta-Analysis of Dietary Interventions and Microbiome in Phenylketonuria.系统评价和饮食干预与苯丙酮尿症微生物组的荟萃分析。
Int J Mol Sci. 2023 Dec 13;24(24):17428. doi: 10.3390/ijms242417428.
5
Nutritional status of adults with phenylketonuria on pegvaliase: A 15-month prospective study.接受培格瓦酶治疗的苯丙酮尿症成人患者的营养状况:一项为期15个月的前瞻性研究。
Mol Genet Metab Rep. 2023 Oct 20;37:101015. doi: 10.1016/j.ymgmr.2023.101015. eCollection 2023 Dec.
6
Expert Consensus on the Long-Term Effectiveness of Medical Nutrition Therapy and Its Impact on the Outcomes of Adults with Phenylketonuria.医学营养治疗的长期疗效及其对成人苯丙酮尿症患者结局影响的专家共识。
Nutrients. 2023 Sep 11;15(18):3940. doi: 10.3390/nu15183940.
7
Complications of the Low Phenylalanine Diet for Patients with Phenylketonuria and the Benefits of Increased Natural Protein.苯丙酮尿症患者低苯丙氨酸饮食的并发症及增加天然蛋白质的益处。
Nutrients. 2022 Nov 23;14(23):4960. doi: 10.3390/nu14234960.
8
Characterization of Choline Nutriture among Adults and Children with Phenylketonuria.成人和儿童苯丙酮尿症患者胆碱营养状况的特点。
Nutrients. 2022 Sep 29;14(19):4056. doi: 10.3390/nu14194056.